Developing a set of indicators to monitor the performance of the pharmaceutical industry:
The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitat...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2023
|
| Schriftenreihe: | OECD Health Working Papers
no.157 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework. |
| Beschreibung: | 1 Online-Ressource (75 p.) 21 x 28cm. |
| DOI: | 10.1787/3b5ca61c-en |
Internformat
MARC
| LEADER | 00000nam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-098549758 | ||
| 003 | DE-627-1 | ||
| 005 | 20231204121054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231204s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/3b5ca61c-en |2 doi | |
| 035 | |a (DE-627-1)098549758 | ||
| 035 | |a (DE-599)KEP098549758 | ||
| 035 | |a (FR-PaOEC)3b5ca61c-en | ||
| 035 | |a (EBP)098549758 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keelara, Rishub |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Developing a set of indicators to monitor the performance of the pharmaceutical industry |c Rishub, Keelara ... [et al] |
| 264 | 1 | |a Paris |b OECD Publishing |c 2023 | |
| 300 | |a 1 Online-Ressource (75 p.) |c 21 x 28cm. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers |v no.157 | |
| 520 | |a The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework. | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Wenzl, Martin |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Waagstein, Lisbeth |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Moens, Marjolijn |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Lopert, Ruth |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/3b5ca61c-en |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 951 | |a BO | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-13-SOC-098549758 |
|---|---|
| _version_ | 1804748624215670784 |
| adam_text | |
| any_adam_object | |
| author | Keelara, Rishub |
| author2 | Wenzl, Martin Waagstein, Lisbeth Moens, Marjolijn Lopert, Ruth |
| author2_role | ctb ctb ctb ctb |
| author2_variant | m w mw l w lw m m mm r l rl |
| author_facet | Keelara, Rishub Wenzl, Martin Waagstein, Lisbeth Moens, Marjolijn Lopert, Ruth |
| author_role | aut |
| author_sort | Keelara, Rishub |
| author_variant | r k rk |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC |
| ctrlnum | (DE-627-1)098549758 (DE-599)KEP098549758 (FR-PaOEC)3b5ca61c-en (EBP)098549758 |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/3b5ca61c-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02777nam a22003732 4500</leader><controlfield tag="001">ZDB-13-SOC-098549758</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20231204121054.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">231204s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/3b5ca61c-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)098549758</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP098549758</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)3b5ca61c-en</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBP)098549758</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Keelara, Rishub</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Developing a set of indicators to monitor the performance of the pharmaceutical industry</subfield><subfield code="c">Rishub, Keelara ... [et al]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (75 p.)</subfield><subfield code="c">21 x 28cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.157</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wenzl, Martin</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waagstein, Lisbeth</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moens, Marjolijn</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopert, Ruth</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/3b5ca61c-en</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-098549758 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-16T15:06:50Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-863 DE-BY-FWS |
| owner_facet | DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (75 p.) 21 x 28cm. |
| psigel | ZDB-13-SOC |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Keelara, Rishub VerfasserIn aut Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] Paris OECD Publishing 2023 1 Online-Ressource (75 p.) 21 x 28cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Health Working Papers no.157 The 2018 OECD report Pharmaceutical Innovation and Access to Medicines noted that public debates about pharmaceutical policy are often marked by a lack of authoritative and commonly accepted information supporting the arguments of the stakeholders involved. A set of agreed indicators would facilitate better informed, more fact-based pharmaceutical policy debates to benefit all stakeholders, including the general public, policy makers, and the industry itself, and could help restore and strengthen trust among them. As part of its broader work agenda on "Increasing the transparency of pharmaceutical markets to inform policies", the OECD undertook a comprehensive analysis to evaluate the feasibility of establishing a set of core indicators. The selection of indicators was guided by the principle that health policy aims to improve population health, and that access to effective medicines produced by a viable industry is essential to achieving that objective. To help policy makers understand how financial resources in the pharmaceutical industry contribute to the research and development of effective products in areas of need, indicators should cover three domains: inputs, including financial flows into the industry; activity, including financial performance and R&D expenditure and activity; and outputs, capturing product outflows and benefit to health systems. This paper presents the key findings on the feasibility of populating indicators to address the input and activity domains within this framework. Social Issues/Migration/Health Wenzl, Martin MitwirkendeR ctb Waagstein, Lisbeth MitwirkendeR ctb Moens, Marjolijn MitwirkendeR ctb Lopert, Ruth MitwirkendeR ctb FWS01 ZDB-13-SOC FWS_PDA_SOC https://doi.org/10.1787/3b5ca61c-en Volltext |
| spellingShingle | Keelara, Rishub Developing a set of indicators to monitor the performance of the pharmaceutical industry Social Issues/Migration/Health |
| title | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_auth | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_exact_search | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_full | Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] |
| title_fullStr | Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] |
| title_full_unstemmed | Developing a set of indicators to monitor the performance of the pharmaceutical industry Rishub, Keelara ... [et al] |
| title_short | Developing a set of indicators to monitor the performance of the pharmaceutical industry |
| title_sort | developing a set of indicators to monitor the performance of the pharmaceutical industry |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/3b5ca61c-en |
| work_keys_str_mv | AT keelararishub developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry AT wenzlmartin developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry AT waagsteinlisbeth developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry AT moensmarjolijn developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry AT lopertruth developingasetofindicatorstomonitortheperformanceofthepharmaceuticalindustry |